BioDelivery Sciences (BDSI) Misses Q4 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bunavail and Belbuca Should Allow BioDelivery Sciences (BDSI) To Outperform - Piper Jaffray
March 11, 2016 7:51 AM ESTPiper Jaffray analyst, David Amsellem, provided an update on BioDelivery Sciences (NASDAQ: BDSI) after the company reported 4Q15. Bunavail access continues to improve and the analyst is positive on the outlook reiterating his Overweight rating.
BioDelivery Sciences reported 4Q15 EPS of $0.19 on revenues of $32M (inclusive of a $30M milestone from Endo associated with the approval of Belbuca in October 2015). Sales of Bunavail, the company's buccal film form of buprenorphine/naloxone for opioid dependence, were $1.5M, and Bunavail now has Medicare/Medicaid access in 26 states. Given the... More
